Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Collen

Showing results (671-680 of 715) with videos related to

Pageof 72
Sort By:
Circulation|February 1, 1991
Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trialJ M Gore, M Sloan, T R Price, et al.
Nature|March 31, 1994
Physiological consequences of loss of plasminogen activator gene function in miceP Carmeliet, L Schoonjans, L Kieckens, et al.
Blood|February 1, 1993
Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinaseP Holvoet, Y Laroche, J M Stassen, et al.
Circulation|September 1, 1988
Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activatorJ A Johns, H K Gold, R C Leinbach, et al.
Bio/Technology (Nature Publishing Company)|February 1, 1994
High yield production and purification of recombinant staphylokinase for thrombolytic therapyB Schlott, M Hartmann, K H Gührs, et al.
The New England Journal of Medicine|March 8, 1984
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarctionF Van de Werf, P A Ludbrook, S R Bergmann, et al.
Circulation|September 1, 1989
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activatorL W Gimple, H K Gold, R C Leinbach, et al.
Lancet (London, England)|November 2, 1985
Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarctionM Verstraete, W Bleifeld, R W Brower, et al.
Neurology|April 1, 1995
Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experienceM A Sloan, T R Price, C K Petito, et al.
Nature Medicine|August 13, 1998
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularizationK Bajou, A Noël, R D Gerard, et al.
Pageof 72

Showing results (671-680 of 715) with videos related to

Sort By:
Pageof 72
Circulation|February 1, 1991
Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trialJ M Gore, M Sloan, T R Price, et al.
Nature|March 31, 1994
Physiological consequences of loss of plasminogen activator gene function in miceP Carmeliet, L Schoonjans, L Kieckens, et al.
Blood|February 1, 1993
Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinaseP Holvoet, Y Laroche, J M Stassen, et al.
Circulation|September 1, 1988
Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activatorJ A Johns, H K Gold, R C Leinbach, et al.
Bio/Technology (Nature Publishing Company)|February 1, 1994
High yield production and purification of recombinant staphylokinase for thrombolytic therapyB Schlott, M Hartmann, K H Gührs, et al.
The New England Journal of Medicine|March 8, 1984
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarctionF Van de Werf, P A Ludbrook, S R Bergmann, et al.
Circulation|September 1, 1989
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activatorL W Gimple, H K Gold, R C Leinbach, et al.
Lancet (London, England)|November 2, 1985
Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarctionM Verstraete, W Bleifeld, R W Brower, et al.
Neurology|April 1, 1995
Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experienceM A Sloan, T R Price, C K Petito, et al.
Nature Medicine|August 13, 1998
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularizationK Bajou, A Noël, R D Gerard, et al.
Pageof 72